EP. 1: Dr. Westin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCLNovember 16th 2022
Jason Westin, MD, FACP, discusses reasons to refer patients with diffuse large B-cell lymphoma to second-line CAR T-cell therapy, CAR T-cell eligibility criteria, and high-risk disease features that may further support the use of CAR T-cell therapy in the second line, rather than chemotherapy.
EP. 2: Dr. Lin on Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCLNovember 16th 2022
Richard J. Lin, MD, PhD, discusses the manufacturing considerations that factor into the CAR T-cell decision-making process in diffuse large B-cell lymphoma, the importance of open communication between community and referral physicians, and how early referral leads to optimal patient outcomes with CAR T-cell therapy.
EP. 3: Dr. Moskowitz on Antibody-Drug Conjugates in Relapsed/Refractory DLBCLNovember 28th 2022
Craig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.